Baselinea | Time after intervention | ||||
---|---|---|---|---|---|
directly | 3 months | 6 months | 9 months | ||
Age, mean (SD); range | 51.80 (10.14); 19.00–79.00 | ||||
Women, n (%) | 128 (44.00) | ||||
Body mass index, mean (SD); range | 26.37 (4.25); 18.37–39.56 | ||||
EQ-5D utility index1, mean (SD); range | 0.79 (0.17); 0.01–1.00 | 0.88 (0.11); 0.36–1.00 | 0.87 (0.12); 0.24–1.00 | 0.85 (0.13); 0.19–1.00 | 0.83 (0.16); 0.08–1.00 |
EQ-VAS2, mean (SD); range | 62.51 (18.01); 15.00–100.00 | 74.88 (17.10); 2.00–100.00 | 74.76 (15.41) 20.00–100.00 | 71.46 (15.52) 18.00–98.00 | 67.23 (18.00) 20.00–100.00 |
Clinically relevant improvement EQ-5D utility index3, n (%) | 164 (56.36) | 160 (54.98) | 130 (44.67) | 107 (36.77) | |
Clinically relevant improvement EQ-VAS3, n (%) | 207 (70.10) | 191 (65.64) | 170 (58.42) | 139 (47.77) |